As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.

A surgeon who took a new drug under clinical trial during cancer treatment is calling on the NHS to approve the drug to tackle ‘inequalities in care’.

Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM, a blood cancer in which abnormal plasma cells build up in the bone marrow, producing large ...

The family of a man who died from an aggressive form of cancer has pleaded with health officials to give the green light to a new treatment, which offers hope of a “normal life”. New father Huw Jones, ...

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the ...

In a study of older adults with advanced cancer, only 8.4% prioritized extending survival compared with 71.7% who prioritized maintaining quality of life (QoL). There were no significant differences ...

HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on ...

The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet ...